Chen R, Udenfriend S, Prince G M, Maxwell S E, Ramalingam S, Gerber L D, Knez J, Medof M E
Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2280-4. doi: 10.1073/pnas.93.6.2280.
The final step in the pathway that provides for glycosylphosphatidylinositol (GPI) anchoring of cell-surface proteins occurs in the lumen of the endoplasmic reticulum and consists of a transamidation reaction in which fully assembled GPI anchor donors are substituted for specific COOH-terminal signal peptide sequences contained in nascent polypeptides. In previous studies we described a human K562 cell mutant line, designated class K, which assembles all the known intermediates of the GPI pathway but fails to display GPI-anchored proteins on its surface membrane. In the present study, we used mRNA encoding miniPLAP, a truncated form of placental alkaline phosphatase (PLAP), in in vitro assays with rough microsomal membranes (RM) of mutant K cells to further characterize the biosynthetic defect in this line. We found that RM from mutant K cells supported NH2-terminal processing of the nascent translational product, preprominiPLAP, but failed to show any detectable COOH-terminal processing of the resulting prominiPLAP to GPI-anchored miniPLAP. Proteinase K protection assays verified that NH2-terminal processed prominiPLAP was appropriately translocated into the endoplasmic reticulum lumen. The addition of hydrazine or hydroxylamine, which can substitute for GPI donors, to RM from wild-type or mutant cells defective in various intermediate biosynthetic steps in the GPI pathway produced large amounts of the hydrazide or hydroxamate of miniPLAP. In contrast, the addition of these nucleophiles to RM of class K cells yielded neither of these products. These data, taken together, lead us to conclude that mutant K cells are defective in part of the GPI transamidase machinery.
为细胞表面蛋白提供糖基磷脂酰肌醇(GPI)锚定的途径的最后一步发生在内质网腔中,由转酰胺反应组成,在该反应中,完全组装好的GPI锚定供体替代新生多肽中包含的特定COOH末端信号肽序列。在先前的研究中,我们描述了一种人类K562细胞突变株系,命名为K类,它能组装GPI途径的所有已知中间体,但未能在其表面膜上展示GPI锚定蛋白。在本研究中,我们使用编码miniPLAP(胎盘碱性磷酸酶(PLAP)的截短形式)的mRNA,与突变K细胞的粗微粒体膜(RM)进行体外测定,以进一步表征该株系中的生物合成缺陷。我们发现,来自突变K细胞的RM支持新生翻译产物preprominiPLAP的NH2末端加工,但未能显示出将所得的prominiPLAP加工成GPI锚定的miniPLAP的任何可检测到的COOH末端加工。蛋白酶K保护试验证实,NH2末端加工的prominiPLAP被适当地转运到内质网腔中。向野生型或在GPI途径中各种中间生物合成步骤有缺陷的突变细胞的RM中添加能替代GPI供体的肼或羟胺,可产生大量miniPLAP的酰肼或异羟肟酸酯。相比之下,向K类细胞的RM中添加这些亲核试剂均未产生这些产物。综合这些数据,我们得出结论,突变K细胞在部分GPI转酰胺酶机制中存在缺陷。